Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term flecainide therapy in type 3 long QT syndrome.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology - 1 Feb 2018

Chorin Ehud, Taub Rivki, Medina Aron, Flint Nir, Viskin Sami, Benhorin Jesaia

Abstract excerpt

Aims: Type 3 long QT syndrome (LQT3) is caused by gain-of-function mutations in the cardiac sodium channel gene (SCN5A). Previous reports on the long-term use of sodium channel blockers in LQT3 are sparse. The objective of the current study was to evaluate the long-term safety and efficacy of flecainide therapy in patients with LQT3 who carry the D1790G SCN5A mutation. Methods and results: The study population...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Brugada Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiac Conduction System Disease

Share to Clinical Decision-Making

Share to Flecainide

Share to Long QT Syndrome

Share to NAV1.5 Voltage-Gated Sodium Channel

Share to Patient Selection

Source

Identifiers

PMID: 28339995
DOI: 10.1093/europace/euw439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term flecainide therapy in type 3 long QT syndrome.PMID 28339995Read ↗

Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.Semantic proximity Read ↗

The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.Semantic proximity Read ↗

A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.Semantic proximity Read ↗

Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.Semantic proximity Read ↗

Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?Semantic proximity Read ↗

Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.Semantic proximity Read ↗

Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.Semantic proximity Read ↗

Sodium channel blockers in the management of long QT syndrome: a system review and meta-analysisSemantic proximity Read ↗

Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.Semantic proximity Read ↗

Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.Semantic proximity Read ↗

Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.Semantic proximity Read ↗

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.